Guard-02: Safety and efficacy of prophylactic use of novel long-acting G-CSF efbemalenograstim α on same-day of chemotherapy in breast cancer patients.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.e24088
Abstract: e24088 Background: Granulocyte colony-stimulating factor (G-CSF) is widely used for prevention of chemotherapy-induced neutropenia (CIN), there is controversy over whether G-CSF can be given within 24 hours after chemotherapy yet. Efbemalenograstim α is a novel… read more here.
Keywords: hours chemotherapy; acting csf; long acting; grade neutropenia ... See more keywords